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Abstract
AIM: To evaluate the clinical usefulness of soluble 
heparin-binding epidermal growth factor (sHB-EGF) as 
a serum biomarker for gastric cancer (GC).
METHODS: Serum sHB-EGF levels were measured 
by a commercially available human HB-EGF ELISA Kit 
and compared among 60 normal controls, 30 high-
risk patients, 37 early gastric cancer (EGC), and 
30 advanced gastric cancer (AGC) through ANOVA 
test. Correlations between serum sHB-EGF and 
clinicopathological features of GC were analyzed through 
Spearman’s correlation. The diagnostic performance of 
serum sHB-EGF for GC was evaluated through receiver 
operating characteristic (ROC) curve and logistic 
regression analysis.
RESULTS: Serum sHB-EGF levels were significantly 
higher in AGC group (314.4 ± 127.5 pg/mL) than EGC 
(165.3 ± 123.2 pg/mL), high-risk (98.7 ± 67.3 pg/mL), 
and control (94.7 ± 83.6 pg/mL) groups (post-hoc 
Bonferroni, all P  < 0.001), respectively. Serum sHB-EGF 
levels were also significantly higher in EGC group than 
high-risk (P  = 0.049) and control (P  = 0.006) groups. 
Clinicopathologically, serum sHB-EGF levels closely 
correlated with depth of invasion (T-stage, γs = 0.669, P  
< 0.001), lymph node metastasis (N-stage, γs = 0.407, 
P  = 0.001), and distant metastasis (M-stage, γs = 0.261, 
P  = 0.030). ROC curve and logistic regression analysis 
demonstrated a remarkable diagnostic potential of 
serum sHB-EGF.
CONCLUSION: Serum sHB-EGF is closely correlated 
with advanced stage GC and can be a promising 
serological biomarker for GC.
Key words: Biomarker; Diagnostic; Gastric cancer; 
Prognostic; Soluble heparin-binding EGF-like growth 
factor
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
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ORIGINAL ARTICLE
HB-EGF is a member of the EGF family[14]. It is 
initially synthesized as a membrane-anchored form 
(pro-HB-EGF), which is subsequently cleaved from 
the membrane by metalloproteinase to produce 
a mature soluble form of HB-EGF (sHB-EGF)[15]. 
Many in vitro studies demonstrated that sHB-EGF 
is a potent mitogen for several types of epithelial 
cells[16-19]. Several studies also demonstrated that 
HB-EGF is overexpressed in human GC cell lines and 
GC tissues[13,19,20]. Therefore, this growth factor has 
potentials as a biomarker for GC. Although tissue 
markers have high specificity, reproducibility, and 
reliability, serological biomarkers are preferable as 
a screening method for GC because tissue markers 
require invasive techniques such as endoscopy and 
biopsy. Because HB-EGF is released into circulation 
as a mature soluble form, this growth factor can 
be measured in serum, and serum levels of this 
soluble factor may reflect the disease progression 
in GC. However, there is little information about the 
serological levels of sHB-EGF according to gastric 
carcinogenic sequence.
In this study, we determined how serum levels 
of sHB-EGF related to the “gastritis-dysplasia-
carcinoma” sequence of gastric carcinogenesis[21] 
and analyzed its correlations with clinicopathological 
features of GC. We also investigated the usefulness 
as a biomarker for GC compared with serum CEA.
MATERIALS AND METHODS
Subjects and clinical information
A total of 157 subjects from Yonsei University Health 
System were enrolled in this study. All subjects 
underwent upper gastrointestinal endoscopy (Types 
XQ-260, Olympus, Tokyo, Japan) with biopsy. The final 
diagnosis was made based on histological findings 
from biopsy or surgical specimens. All patients were 
diagnosed for the first time during the enrollment 
period, and blood samples were collected before 
they received any treatments. Blood samples were 
stored as serum fractions at -80 ℃ until analysis. The 
Institutional Review Board of Yonsei University Health 
System approved the current study, and written 
informed consent was obtained from all participants in 
accordance with the Declaration of Helsinki.
Subjects who suffered from chronic diseases such 
as liver cirrhosis, chronic renal disease, and diabetes 
mellitus were excluded from this study. Subjects with 
other cancers and other gastric neoplasms such as 
gastrointestinal stromal tumors, mucosa-associated 
lymphoid tissue lymphomas, and neuroendocrine 
tumors were also excluded. Patients who previously 
received any treatment for GC or its premalignant 
lesions were also excluded.
Subjects were classified into the following four 
groups according to the “gastritis-dysplasia-carcinoma” 
sequence of gastric carcinogenesis[21]: control group, 
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Core tip: Early detection of gastric cancer (GC) is most 
important issue. Although endoscopic examination is 
an ideal, highly reliable technique for early detection 
of GC, it has limitation because of its high cost and 
invasiveness. Therefore, inexpensive, comfortable, 
reliable and less-invasive biomarkers need to be 
identified. Here, we reported that serum levels of 
soluble HB-EGF (sHB-EGF) closely correlated with 
advanced TNM stage and was higher in EGC than high-
risk group. We also identified a remarkable diagnostic 
accuracy of serum sHB-EGF for GC. To our knowledge, 
this is the first study to validate sHB-EGF as a desirable 
serum biomarker for GC.
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INTRODUCTION
Although the incidence of gastric cancer (GC) has 
decreased over the past few decades, it is still a 
serious health problem because it is the second most 
frequent cause of cancer-related deaths worldwide[1], 
which may be originated from that the prognosis of 
advanced gastric cancer (AGC) remains poor despite 
the recent advances in treatment strategies[2]. In 
contrast, the prognosis of early gastric cancer (EGC) 
is favorable[3]. These facts strongly support the clinical 
importance of early detection of GC. Endoscopic 
examination is an ideal, highly reliable technique for 
early detection of GC and its premalignant lesions[4]. 
However, its usefulness as a routine screening 
method is somewhat limited because of its high cost 
and the risk associated with this invasive procedure. 
Therefore, inexpensive, comfortable, reliable and 
less-invasive biomarkers such as accurate serological 
biomarker need to be identified.
Carcinoembryonic antigen (CEA), a well-known 
gastrointestinal tumor-related biomarker, was initially 
applied as a biomarker for GC. However, recent 
studies have found that CEA does not demonstrate 
the sensitivity or specificity needed to effectively 
screen for GC[5].
Activation of the epidermal growth factor (EGF) 
and epidermal growth factor receptor (EGFR) families 
is known to be associated with the progression of 
various tumor types[6]. Activation of EGF-EGFR axis is 
also associated with tumor growth, serosal invasion, 
and resultant poor prognosis of GC patients[7-9]. EGFR 
has seven ligands. Of these ligands, heparin-binding 
EGF-like growth factor (HB-EGF) is in particular 
thought to be associated with GC development and 
progression[10-13].
which included normal mucosa or acute and chronic 
gastritis; high-risk group, which included intestinal 
metaplasia (IM) and dysplasia; EGC group; and 
AGC group. Both age and sex were matched in all 
groups. All patients in the cancer groups underwent 
imagining studies including chest X-ray, abdominal-
pelvic helical computed tomography, and whole-body 
positron emission tomography to determine TNM 
stage. TNM stage for GC was evaluated according 
to the 7th International Union Against Cancer-TNM 
stage guidelines for GC[22] based on radiological 
studies or surgical findings. Helicobacter pylori (H. 
pylori) infection was determined by staining of gastric 
tissue with Giemsa solution (Sigma, MO, United 
States). Glandular atrophy and IM were diagnosed 
according to the updated Sydney classification[23], 
and pathological determination of differentiation 
status (well, moderate, poor, and signet-ring cell) was 
performed according to the Lauren classification.
Measurement of serum CEA and HB-EGF levels
Serum CEA levels were measured by the Beckman 
Access CEA assay (Beckman Coulter Inc., MN, United 
States). Serum sHB-EGF levels were measured 
by a commercially available human HB-EGF ELISA 
Kit (DY259, RD, MN, United States) according to 
the manufacturer’s instructions. Briefly, 96-well 
microplates were coated with capture antibody (80 
μg/well, goat anti-human HB-EGF) at 4 ℃ for 16 h. 
After washing, the plates were blocked with Reagent 
Diluent (provided in kit) and then incubated for 1 h 
at room temperature (RT). After washing, 100 μL of 
diluted sample, standard, and control were added to 
each well. The microplates were then incubated for 
2 h at RT. Subsequently, microplates were washed 
and then detection antibody was added (10 ng/well, 
biotinylated goat anti-human HB-EGF). The plates 
were then incubated for 2 h at RT. After washing, 
streptavidin-HRP was added and incubated for 
20 min at RT in the dark place. Plates were then 
washed again, and 100 μL of chromogen (H2O2 and 
tetra-methylbenzidine) was added to each well. The 
enzyme reaction proceeded for 20 min at RT in the 
dark place. The chromogenic substrate reaction was 
stopped by the addition of stop solution (2 mol/L 
H2SO4) and the absorbance was read at 450/570 
nm. The final values were calculated based on a 
calibration curve prepared from standards. The 
ELISA for sHB-EGF levels was tested in triplicate.
Statistical analysis
To calculate the appropriate sample size for each 
group, Russ Lenth’s interactive power/sample size 
online calculator was used. Under assuming that 
there were 4 comparison groups, the estimated 
standard deviation (SD) was 1, and the confidence 
level was 0.05, sample size of ≥ 30 in each group 
achieved a statistical power > 80% using one-way 
analysis of variance (ANOVA).
For statistical analysis for current data, SPSS 
version 20.0 (IBM Corp., NY, United States) was 
used. P values < 0.05 were considered statistically 
significant. Values (sHB-EGF, CEA) were expressed 
as the mean with the 25%-75% SD. Means of each 
group was compared by ANOVA test with multiple 
comparisons by using the post-hoc Bonferroni method. 
An independent sample t-test was used to compare 
the mean between the cancer groups vs non-cancer 
groups. Spearman’s correlation (coefficient, γs) was 
used to assess the relationship between continuous 
variables and non-continuous variables, and Pearson’
s correlation (coefficient, γp) was used to assess the 
relationship between continuous variables. Nominal 
data were compared by χ2 test. The receiver operating 
characteristic (ROC) curves was conducted and area 
under the curve (AUC) was calculated to compare 
the diagnostic accuracy between serum sHB-EGF and 
serum CEA. Logistic regression analysis was performed 
to obtain the best sensitivity/specificity to predict the 
presence of GC as a single-marker or as a part of 
multiple-markers panel. Each marker was included as 
a linear term.
RESULTS
Baseline characteristics of subjects and serum levels of 
sHB-EGF and CEA according to disease groups
The 157 subjects are composed of 60 individuals/
patients with normal mucosa or gastritis (control 
group), 30 patients with IM/dysplasia (high-risk 
group), 37 patients with EGC (EGC group), and 30 
patients with AGC (AGC group). The control group 
was further subdivided into two subgroups; patients 
with normal mucosa/chronic superficial gastritis 
(CSG, n = 30) and patients with chronic atrophic 
gastritis (CAG, n = 30) because the risk of GC 
development was different between CSG and CAG. 
The normal mucosa/CSG group was also further 
subdivided into normal mucosa (n = 15) or CSG 
(n = 15) because gastric inflammation status may 
affect sHB-EGF levels comparing to normal mucosa. 
The clinical and histopathological features of subjects 
in each group are described in Table 1. There were 
no significant differences in distribution of age and 
sex, and the status of H. pylori infection among 
the disease groups (χ 2, all P > 0.05). In the cancer 
groups, the location of primary tumor did not differ 
(P > 0.05), while histological differentiation, primary 
tumor size, and TNM stage were significantly different 
between the EGC and AGC groups (all P < 0.05).
Serum sHB-EGF levels increased along the GC 
carcinogenic sequence, and the differences among 
the groups were statistically significant (ANOVA, 
P < 0.001; Table 2). Serum sHB-EGF levels were 
significantly higher in the AGC group (314.4 ± 
127.5 pg/mL) compared with those of EGC (165.3 
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not affected by sex (γs = 0.138, P = 0.076) or the 
status of H. pylori infection (γs = -0.054, P = 0.486), 
whereas these levels were negatively correlated with 
age (γp = -0.265, P = 0.001). However, serum sHB-
EGF levels were not closely correlated with age when 
analysis was performed in just non-cancer groups 
(γp = 0.108, P = 0.313; Table 6). In contrast, when 
analysis was performed within the cancer groups, 
the serum sHB-EGF levels were negatively correlated 
with age (γp = -0.314, P = 0.010). This result implies 
that serum sHB-EGF levels are affected by the age 
of patients with GC; relatively younger patients 
with GC had more highly elevated sHB-EGF levels 
compared with relatively older patients with GC. On 
the other hand, serum CEA levels were not affected 
by sex, age and the status of H. pylori infection (all 
P > 0.05; Table 5).
Histopathologically, there were no significant 
relationships between serum sHB-EGF levels 
and the histological differentiation of GC (Lauren 
classification system), although sHB-EGF levels tend 
to be higher in diffuse-type than in intestinal-type (γs 
= 0.214, P = 0.078; Table 5). Serum sHB-EGF levels 
were not also affected by primary tumor location (γs 
= −0.054, P = 0.652; Table 5).
On the other hand, serum sHB-EGF levels were 
± 123.2 pg/mL), high-risk (98.7 ± 67.3 pg/mL), 
and control (94.7 ± 83.6 pg/mL) groups (post-hoc 
Bonferroni, all P < 0.001), respectively. Serum sHB-
EGF levels were also significantly higher in the EGC 
groups than the high-risk (P = 0.049) and control 
(P = 0.006) groups, respectively. However, there 
was not a significant difference between the high-
risk and control groups (P > 0.05). Serum sHB-EGF 
levels were also not significantly different between 
the CAG and CSG groups (P > 0.05), or between 
the CSG and normal mucosa groups (P > 0.05), 
respectively (Table 3). On the other hand, serum 
CEA levels were not significantly different among the 
control, high-risk, and EGC groups. The AGC group 
was the only population with significantly elevated 
serum CEA levels (P = 0.001), especially in the case 
with distant metastasis. When serum sHB-EGF levels 
were compared between cancer and non-cancer 
groups, they were significantly higher in the cancer 
groups (232.1 ± 144.9 pg/mL) than in the non-
cancer groups (96.0 ± 78.2 pg/mL; t-test, P < 0.001; 
Table 4).
Correlations between serum sHB-EGF levels and 
clinicopathological characteristics of subjects
Table 5 shows that serum sHB-EGF levels were 
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Table 1  Baseline characteristics of subjects in each group
Groups Control2 (n  = 60) High-risk3 (n  = 30) EGC (n  = 37) AGC (n  = 30) P  value4
Clinical features
Age (mean ± SD, yr) 56.5 ± 11.1 66.2 ± 7.6 58.3 ± 10.6 56.3 ± 10.3    0.856
Sex (male:female, n) 37:23 19:11 22:15 17:13    0.953
H. pylori infection (-/+, n) 35:25 17:13 22:15 20:10    0.857
Histopathological features
   Histology (well:mod:poorly:signet) NS NS 14:9:7:7 2:6:16:6    0.006
   Tumor location (lower:middle:upper)1 NS NS 20:13:4 18:9:3    0.884
   Size of tumor (mean ± SD, cm) NS NS 3.9 ± 1.2 5.0 ± 1.3    0.010
   T-stage (T1a:T1b:T2:T3:T4) NS NS 31:6:0:0:0 0:0:15:4:11 < 0.001
   N-stage (N0:N1:N2:N3) NS NS 35:2:0:0 15:2:4:9 < 0.001
   Distant metastasis (M0:M1) NS NS 37:0 25:5 < 0.001
   Overall stage (Ⅰ:Ⅱ:Ⅲ:Ⅳ) NS NS 37:0:0:0 7:12:6:5 < 0.001
1Tumor location is divided into three areas: lower third (antrum-angle), middle third (low body-middle body), and upper third (upper body-cardia). 
2Control group includes individuals with normal mucosa or patients with simple chronic superficial gastritis and chronic atrophic gastritis. 3High-risk 
group included patients with intestinal metaplasia and dysplasia. 4Continuous data were compared by ANOVA test and nominal data by χ 2 test. P < 0.05 
(two-tailed) was considered statistically significant. AGC: Advanced gastric cancer; EGC: Early gastric cancer; H. pylori: Helicobacter pylori; Mod: Moderate-
differentiated carcinoma; Poorly: Poorly-differentiated carcinoma; SD: Standard deviation; Signet: Signet ring cell carcinoma; Well: Well-differentiated 
carcinoma.
Table 2  Serum levels of soluble heparin-binding epidermal growth factor-like growth factor and carcinoembryonic antigen according 
to disease groups
Groups Control2 (n  = 60) High-risk3 (n  = 30) EGC (n  = 37) AGC (n  = 30) P  value4
Serum sHB-EGF1 (pg/mL) 94.7 ± 83.6 98.7 ± 67.3 165.3 ± 123.2 314.4 ± 127.5 < 0.001
Serum CEA1 (ng/mL) 1.8 ± 1.5 2.2 ± 1.1 2.4 ± 1.4 4.5 ± 5.1     0.001
1All tested values are expressed as the mean ± standard deviation. 2Control group includes individuals with normal mucosa or patients with simple chronic 
superficial gastritis and chronic atrophic gastritis. 3High-risk group included patients with intestinal metaplasia and dysplasia. 4One-way analysis of 
variance (ANOVA) test with the multiple comparisons by the post-hoc Bonferroni method is applied to compare the differences in means among disease 
groups. P < 0.05 (two-tailed) was considered statistically significant. AGC: Advanced gastric cancer; EGC: Early gastric cancer; CEA: Carcinoembryonic 
antigen; sHB-EGF: Soluble heparin-binding EGF-like growth factor.
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closely correlated with depth of invasion (T-stage, 
γs = 0.669, P < 0.001), lymph node metastasis 
(N-stage, γs = 0.407, P= 0.001), distant metastasis 
(M-stage, γs = 0.261, P = 0.030), and overall stage 
(γs = 0.570, P < 0.001) respectively (Table 5). To 
analyze the relationship between serum sHB-EGF 
levels and primary GC size, patients were divided into 
3 groups based on the tumor size: < 3 cm, 3-5 cm, 
and > 5 cm. Table 5 shows that primary GC size was 
positively correlated with serum sHB-EGF levels (γs 
= 0.237, P = 0.048). On the other hand, serum CEA 
levels were only correlated with tumor size (γs = 0.382, 
P = 0.006) and distant metastasis (γs = 0.362, P = 
0.002). Collectively, histopathological results suggest 
that serum sHB-EGF levels were closely correlated 
with advanced stage and poor prognosis of GC.
Diagnostic accuracy of serum sHB-EGF levels for 
prediction of GC
ROC curve was generated and AUCs were calculated 
to compare the diagnostic accuracy of serum sHB-
EGF with serum CEA for prediction of GC (Figure 
1). The AUC of serum sHB-EGF was 0.85 (95%CI: 
0.79-0.91), and those of serum CEA was 0.64 
(95%CI: 0.55-0.73). This analysis indicates that 
serum sHB-EGF has a higher diagnostic accuracy to 
predict the presence of GC compared with CEA.
Logistic regression analysis further confirmed 
the remarkable diagnostic accuracy of serum sHB-
EGF for GC; the sensitivity and specificity of serum 
sHB-EGF levels for diagnosis of GC were 76.1% and 
76.5% (cut-off point, 0.38; Table 7). These values 
are superior to those of serum CEA (sensitivity, 
62.1%; specificity, 51.8%; cut-off point, 0.38). 
When serum sHB-EGF was combined with serum 
CEA, the sensitivity was slightly increased; the 
sensitivity was 77.3% and specificity was 76.5% 
(cut-off point, 0.38), respectively. When serum sHB-
EGF was combined with serum CEA, the sensitivity 
was slightly increased; the sensitivity and specificity 
were 77.3% and 76.5% (cut-off point, 0.38). 
Collectively, serum sHB-EGF exhibited a remarkable 
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Table 3  Serum levels of soluble heparin-binding epidermal 
growth factor-like growth factor between normal mucosa/
chronic superficial gastritis and chronic atrophic gastritis or 
between normal mucosa and chronic superficial gastritis
Groups Serum sHB-EGF1 (pg/mL)
Normal mucosa/CSG (n = 30)   86.4 ± 73.5
CAG (n = 30) 102.9 ± 93.1
P value2 0.449
Normal mucosa (n = 15)   83.1 ± 59.0
CSG (n = 15)   89.7 ± 87.6
P value2 0.811
1Tested value is expressed as the mean ± SD. 2An independent sample t-test 
is applied to compare the differences of means between two groups. P < 
0.05 (two-tailed) was considered statistically significant. sHB-EGF: Soluble 
heparin-binding EGF-like growth factor. CSG: Chronic superficial gastritis; 
CAG: Chronic atrophic gastritis.
Table 4  Serum levels of soluble heparin-binding epidermal 
growth factor-like growth factor and carcinoembryonic 
antigen between non-cancer and cancer groups
Groups Non-cancer2 
(n  = 90)
Cancer3 
(n  = 67)
P  value4
Serum sHB-EGF1 (pg/mL) 96.0 ± 78.2 232.1 ± 144.9 < 0.001
Serum CEA1 (ng/mL) 1.9 ± 1.4 3.3 ± 3.7     0.004
1All tested values are expressed as the mean ± SD. 2Non-cancer groups 
include normal/gastritis group and IM/dysplasia group. 3Cancer 
groups include early gastric cancer (EGC) and advanced gastric cancer 
(AGC) groups. 4An independent sample t-test is applied to compare the 
differences of means between non-cancer and cancer groups. P < 0.05 (two-
tailed) was considered statistically significant. CEA: Carcinoembryonic 
antigen; sHB-EGF: Soluble heparin-binding EGF-like growth factor.
Table 5  Correlations between serum soluble heparin-
binding epidermal growth factor-like growth factor and 
clinicopathological characteristics of each group
Clinicopathological characteristics Serum sHB-EGF Serum CEA
γs (P  value) γs (P  value)
Age (yr)1 -0.265 (0.001) -0.087 (0.275)
Sex (male:female)  0.138 (0.076) -0.021 (0.792)
H. pylori infection (-/+) -0.054 (0.486) -0.114 (0.151)
Histology (well:mod:poorly:signet)  0.214 (0.078)  0.090 (0.465)
Tumor location (lower:middle:upper) -0.052 (0.652) -0.048 (0.691)
T-stage (T1a:T1b:T2:T3:T4)  0.669 (< 0.001)  0.201 (0.101)
N-stage (N0:N1:N2:N3)  0.407 (0.001)  0.073 (0.552)
Distant metastasis (M0:M1)  0.261 (0.030)  0.328 (0.006)
Overall stage (Ⅰ:Ⅱ:Ⅲ:Ⅳ)  0.570 (< 0.001)  0.229 (0.060)
Size of tumor (< 3 cm; 3-5 cm and > 5 
cm)2
 0.237 (0.048)  0.362 (0.002)
1This value is continuous variable. Thus, correlation is evaluated by 
Pearson’s correlation (γp). 2Subjects were classified into three groups 
according to primary GC size: < 3 cm, 3-5 cm, and > 5 cm to analyze the 
relationship between serum HB-EGF levels and primary GC size. CEA: 
Carcinoembryonic antigen; H. pylori: Helicobacter pylori; Mod: Moderate-
differentiated carcinoma; Poorly: Poorly-differentiated carcinoma; Signet: 
Signet ring cell carcinoma; sHB-EGF: Soluble heparin-binding EGF-
like growth factor; Well: Well-differentiated carcinoma; γs: Spearman’s 
correlation coefficient. P < 0.05 (two-tailed) was considered statistically 
significant. Statistically significant values are given in bold print.
Table 6  Pearson’s correlation between serum soluble heparin-
binding epidermal growth factor-like growth factor and age in 
non-cancer groups vs  cancer groups
Groups Serum sHB-EGF Serum CEA
γp (P  value) γp (P  value)
Non-cancer groups1 Age -0.108 (0.313)  0.122 (0.265)
Cancer groups2 Age -0.314 (0.010) -0.187 (0.133)
1Non-cancer groups include normal/gastritis and IM/dysplasia groups. 
2Cancer groups include EGC and AGC groups. γp: Pearson’s correlation 
coefficient. Statistically significant values are given in bold print. AGC: 
Advanced gastric cancer; EGC: Early gastric cancer; sHB-EGF: Soluble 
heparin-binding epidermal growth factor-like growth factor; CEA: 
Carcinoembryonic antigen.
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diagnostic accuracy to predict GC both as a single 
biomarker and as a part of multiple-markers panel 
in GC (Table 7).
DISCUSSION
Increased EGFR levels are associated with poor prog-
nosis in patients with GC[10,24]. HB-EGF, a ligand of 
the EGFR family, is initially synthesized as a pro-
HB-EGF, a membrane-bound precursor form. It is 
later released into circulation as a soluble, mature 
form[15]. This sHB-EGF activates EGFR and acts as 
a potent growth factor[16-19]. HB-EGF is a critical 
molecular component of many normal physiological 
processes[14]. However, uncontrolled HB-EGF ex-
pression is linked to tumor formation. Thus, HB-EGF 
may become a promising biomarker or treatment 
target for cancer. Several studies have shown that 
HB-EGF is overexpressed in GC tissues and GC cell 
lines[20], and overexpressed HB-EGF is correlated 
with far-advanced stage of GC[10]. However, there 
is little quantitative data demonstrating the clinical 
significance of serum sHB-EGF in relation to GC 
tumorigenesis and progression such as TNM stage. 
There is also little known about the usefulness of this 
soluble factor as a biomarker for GC. In this study, 
we gathered quantitative information about the 
clinical significance of serum sHB-EGF levels in GC 
and validated serum sHB-EGF as a useful and reliable 
serological biomarker for GC. 
We divided the subjects into 4 disease groups 
based on the theory of gastric carcinogenesis 
(gastritis-dysplasia-carcinoma)[21]: normal mucosa/
gastritis (control), IM/dysplasia (high-risk), EGC, 
and AGC. Control group included subjects with 
normal gastric mucosa, simple CSG, and CAG be-
cause these patients have a relatively lower risk of 
GC development compared with IM/dysplasia. We 
did not subdivide patients into IM and dysplasia 
(adenoma) in the high-risk group because the num-
ber of subjects in each group was too small to be 
determined statistically significant. We divided the 
cancer patients into EGC and AGC groups because the 
prognosis is definitively different between EGC and 
AGC[1,3]. Interestingly, we observed that serum sHB-
EGF levels increased along the carcinogenic sequence, 
although there was no statistically significant difference 
between the high-risk and control groups (Table 2). 
Serum sHB-EGF levels were also not significantly 
different between CAG and CSG groups or between 
CSG and normal mucosa groups in the control group 
(Table 3). However, significant differences were 
observed between the EGC and control groups, or 
the EGC and high-risk groups, respectively (post-
hoc Bonferroni, all P < 0.05). Serum sHB-EGF levels 
were also significantly higher in AGC group compared 
with the other groups (post-hoc Bonferroni, all P < 
0.001). This result suggests that circulating sHB-
EGF plays an important role in GC tumorigenesis 
and progression, and it is valuable to investigate 
the usefulness of serum sHB-EGF as a serological 
biomarker or treatment target for GC. 
To validate serum sHB-EGF as a desirable serum 
biomarker to predict the presence of GC, we generated 
ROC curves and calculated AUC values. We also 
performed logistic regression analysis to determine 
the best sensitivity and specificity for prediction of 
GC (Figure 1 and Table 7). We compared the results 
from sHB-EGF with the results from CEA, a well-
known gastrointestinal tumor biomarker. Sensitivity/
specificity of serum CEA for detection of GC were 
only around 50%-60% (Table 7), consistent with 
other previous studies[5,25]. However, the sensitivity 
and specificity of serum sHB-EGF were both greater 
than 75% (Table 7). When serum sHB-EGF was 
combined with serum CEA, the sensitivity was 
slightly elevated (76.1%→77.3%, Table 6). These 
are notable results compared with previous GC 
biomarker studies[5,25-27].
Clinicopathologically, serum sHB-EGF levels were 
closely correlated with depth of invasion, lymph 
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Table 7  Logistic regression determination of the diagnostic 
accuracy of serum soluble heparin-binding epidermal growth 
factor-like growth factor compared with those of serum 
carcinoembryonic antigen for prediction of gastric cancer
Markers1 Cut-off point2 Sensitivity Specificity
Serum sHB-EGF 0.38 76.1% 76.5%
Serum CEA 0.38 62.1% 51.8%
Serum sHB-EGF + CEA 0.38 77.3% 76.5%
1Each marker is included as a linear term and evaluated as a panel from 
one to two markers combination. 2Cut-off point means the probability cut-
off point to classify subjects as having gastric cancer (GC) or not in binary 
logistic regression. CEA: Carcinoembryonic antigen; sHB-EGF: Soluble 
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Figure 1  Receiver operating characteristic curve for serum soluble 
heparin-binding epidermal growth factor-like growth factor compared with 
the curve for serum carcinoembryonic antigen to predict gastric cancer. 
ROC: Receiver operating curve; sHB-EGF: Soluble heparin-binding epidermal 
growth factor-like growth factor; CEA: Carcinoembryonic antigen; AUC: Area 
under the ROC curve.
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node metastasis, distant metastasis, and primary 
tumor size (Table 5). This implies that sHB-EGF is 
involved not only in GC tumorigenesis, but also in 
GC expansion, invasion, and metastasis. This result 
is consistent with previous studies[10,11]. To our 
knowledge, this is the first study to evaluate serum 
sHB-EGF levels quantitatively according to the gastric 
carcinogenic sequence, to analyze the correlations 
between serum sHB-EGF and clinicopathological 
features of GC, such as TNM stage, and to validate 
serum sHB-EGF as a desirable serological biomarker 
for GC.
Previous studies reported that sHB-EGF levels 
were influenced by H. pylori infection[11]. However, in 
our study, serum sHB-EGF levels were not correlated 
with the status of H. pylori infection (Table 5). This 
discrepancy may be originated from the differences 
in the genetic background of enrolled subjects or 
different strains of H. pylori between the two studies 
because variation in the clinical presentation of H. 
pylori infection is attributable to strain diversity and 
host susceptibility[28,29]. However, we did not study 
about this in the current study.
A previous study showed that the activity of 
pro-HB-EGF was higher in intestinal type of GC 
compared with diffuse type of GC[13]. However, the 
relationship between the activity of sHB-EGF levels 
and histological differentiation has not been yet 
evaluated in previous studies. In this study, we 
observed that serum sHB-EGF levels tend to be 
higher in diffuse type than intestinal type of GC 
although it was not statistically significant (P = 0.078, 
Table 5). A study group reported that sHB-EGF 
promotes peritoneal carcinomatosis in patients with 
GC[10]. Peritoneal carcinomatosis occurs frequently 
in patients with diffuse scirrhous type of GC. These 
past reports support our current results. However, 
to confirm this, a further study may be necessary in 
the future.
We also observed that serum sHB-EGF levels 
were inversely correlated with age in GC patients 
(Table 5), whereas this value was not affected by 
age in non-cancer groups (Table 6), which implies 
that age itself may not affect the serum levels of 
sHB-EGF. Rather, higher levels of serum sHB-EGF in 
relatively younger GC patients than older patients 
may suggest that serum sHB-EGF may contribute 
to GC carcinogenesis especially in young age. 
However, we cannot currently explain the underlying 
mechanism of this phenomenon.
One of limitations of this study is the relatively 
small sample sizes, although statistical power of 
the current sample size of each group was > 80%. 
Additionally, we did not evaluate the relationship 
between serum sHB-EGF levels and prognosis of 
GC patients by directly comparing overall survival 
because the observation period was too short 
to evaluate the survival of the patients with GC. 
However, Table 5 showing the close correlations 
between high-levels of serum sHB-EGF and the 
presence lymph node and distant metastasis may 
support the correlation between high-levels of 
serum sHB-EGF and poor prognosis of GC indirectly 
because these two factors are the most important 
prognostic indicators for GC patients[30-32].
In conclusion, in this study, we evaluated the 
clinical significance of serum sHB-EGF levels in 
GC and validated serum sHB-EGF as a promising 
diagnostic and prognostic biomarker for GC. Our 
results also provide a rationale for blockade of sHB-
EGF as a promising effective treatment target for 
GC, especially for advanced GC. Actually, several 
past studies have shown a remarkable antitumor 
effect of an HB-EGF inhibitor alone or in combination 
with various anticancer agents in cancer including 
GC[12,33]. To confirm this, we will conduct a large-
scaled study in the future.
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it can be measured in serum and can be used as a serum biomarker for GC. 
The authors determined how serum levels of sHB-EGF related to the ‘gastritis-
dysplasia-carcinoma’ sequence of gastric carcinogenesis and validated its 
usefulness as a biomarker for GC compared with serum CEA, a classic 
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Recent reports showed that increased epidermal growth factor receptor levels 
are associated with poor prognosis in patients with GC and HB-EGF expression 
is linked to tumor formation although HB-EGF is a critical molecular component 
of many normal physiological processes. Thus, HB-EGF may become a 
promising biomarker or treatment target for GC. Several studies have shown 
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data demonstrating the clinical significance of serum sHB-EGF in relation to GC 
tumorigenesis and progression such as TNM stage.
This is the first study to evaluate serum sHB-EGF levels quantitatively 
according to the gastric carcinogenic sequence, to analyze the correlations between 
serum sHB-EGF and clinicopathological features of GC, such as TNM stage, and to 
validate serum sHB-EGF as a desirable serological biomarker for GC.
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The study results suggest that sHB-EGF are closely correlated with advanced 
TNM stage and higher in early gastric cancer (EGC) group than high-risk group, 
and higher in advanced gastric cancer group than EGC group. Additionally, this 
study demonstrated a remarkable diagnostic accuracy of serum sHB-EGF for 
GC.
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